ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Takeda announces results from Phase IIIb/IV clinical trial for ADYNOVATE
July 08, 2019The PROPEL study is a PROspective, randomized, multi-center study comparing the safety and efficacy of ADYNOVATE following PK-guided prophylaxis targeting two different Factor Eight (FVIII) through activity Levels in subjects with severe hemophilia A.
Pharma Sources Insight January 2025
